Recursion Pharmaceuticals’ (RXRX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX) in a research report report published on Thursday,Benzinga reports. The firm currently has a $8.00 target price on the stock.

A number of other brokerages also recently commented on RXRX. Bank of America lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday. UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $3.67 on Thursday. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a fifty-two week low of $2.98 and a fifty-two week high of $7.89. The business has a fifty day moving average of $4.18 and a 200-day moving average of $4.70. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -2.48 and a beta of 0.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 66.70% and a negative net margin of 863.37%.The firm had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $24.56 million. During the same quarter last year, the business posted ($0.53) EPS. The firm’s quarterly revenue was up 671.7% compared to the same quarter last year. As a group, analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ben R. Taylor sold 13,426 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total transaction of $41,352.08. Following the completion of the sale, the chief financial officer directly owned 1,195,349 shares in the company, valued at $3,681,674.92. This represents a 1.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the transaction, the insider owned 611,135 shares in the company, valued at $2,695,105.35. The trade was a 16.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 819,212 shares of company stock valued at $3,523,950 in the last ninety days. Company insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors have recently modified their holdings of RXRX. Vanguard Group Inc. raised its holdings in Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after buying an additional 7,407,606 shares during the period. State Street Corp increased its position in shares of Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after acquiring an additional 7,064,963 shares in the last quarter. Norges Bank purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $23,473,000. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 11.2% during the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after acquiring an additional 3,771,357 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG acquired a new position in shares of Recursion Pharmaceuticals during the 3rd quarter valued at $7,954,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

More Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Recursion reported narrower-than-expected Q4 loss (EPS -$0.21 vs. -$0.28 est.) and materially beat revenue estimates, driven partly by partner milestones. The results and upbeat metrics were the primary catalyst lifting the stock after the print. RXRX Q4 Loss Narrower Than Expected
• Positive Sentiment: Revenue jump / partner milestone extends runway — FY2025 revenue rose materially (reported ~$74.7M), with Roche-related milestone revenue cited as extending Recursion’s cash runway into 2028, reducing near-term financing risk. Recursion Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress — Management highlighted advancement of programs (e.g., REC-4881 entering clinical stages), signalling the company is moving from discovery to clinical validation — a tangible de‑risking step for an AI-driven biotech. Recursion Hits Clinical Milestones
• Positive Sentiment: Analyst support — Needham reaffirmed a “buy” and set an $8 price target, giving investors a visible upside case and supporting momentum after the print. Needham Rating
• Neutral Sentiment: Earnings call emphasized strategy and partnerships — Management framed 2025 as a transition year (scale data + ML + clinical starts); useful for long-term thesis but not an immediate earnings driver. Earnings Call Summary
• Neutral Sentiment: Disclosure/analysis availability — Full call transcript and presentation were posted (useful for modelers and event traders). Earnings Presentation
• Negative Sentiment: Still unprofitable and wide negative margins — Despite the beat, Recursion remains loss-making (negative net margin/ROE) and analysts forecast negative FY EPS, leaving valuation and path to sustained profitability as open questions. AAII Analysis
• Negative Sentiment: Technical / liquidity headwinds — The stock traded below key moving averages with volume below its recent average, and remains volatile; those factors can pressure price even after positive news. Market Reaction

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.